CRP and infection: This aligns with observations from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) study, where improved clinical outcomes in patients were associated with reduced CRP levels independent of lipid profiles [49].